Art. -Nr.: HY-B1341

Norethynodrel

(Synonyms: Enidrel; SC-4642; NSC 15432)

Norethynodrel (Enidrel; SC-4642) is an orally active progestogen analog that reduces estrogen-like effects and enhances progestogen-like responses in endometrial stromal cells. Norethynodrel also promotes cell maturation and predecidual cell formation by inducing organelle hyperplasia and glycogen accumulation. Norethynodrel competitively inhibits drug-metabolizing enzymes in rat liver microsomes, thereby prolonging Pentobarbital sleep time, while exhibiting multiple effects including reduced body weight gain, attenuated heart rate elevation and ovulation inhibition. In mouse models, Norethynodrel significantly increases the incidence of mammary adenocarcinoma, cervical cancer and pituitary tumors. Norethynodrel can be used for mechanism research on related diseases such as mammary adenocarcinoma, cervical cancer, ovarian tubular adenoma and pituitary adenoma.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

CAS. Nr.: 68-23-5
Formel: C₂₀H₂₆O₂
Molecular Weight:298.42

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Norethynodrel Chemical Structure

CAS. Nr.: 68-23-5

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- In Vitro
- In Vivo
Chemical Information
Lösungsmittel & Löslichkeit
- In Vitro
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Alle Endogenous Metabolite Isoform-spezifische Produkte anzeigen :

In Vitro

Norethynodrel (10-100 μM; 20 h) weakly inhibits Sprague-Dawley rat hepatic microsomal pentobarbital hydroxylation (K_i=24 μM), aminopyrine N-demethylation, and aniline p-hydroxylation in vitro, with greater inhibition observed at 100 μM than at 10 μM^[3].
Norethynodrel (10-100 μM) acts as a Type I substrate for Sprague-Dawley rat hepatic microsomal cytochrome P-450, exhibiting a spectral dissociation constant (K_s) of 24 μM and a maximum difference absorbance (ΔAmax) of 0.029^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Norethynodrel (125-500 μg/20 g body weight; s.c.; twice weekly; up to 106 weeks) induces a significant increase in mammary gland development, hyperplastic alveolar nodules, type B mammary adenocarcinomas (8 cases), and cervical carcinomas (6 cases) in virgin female A/J mice, while also causing structural changes in ovaries, uteri, and adrenals^[2].
Norethynodrel (10-50 mg/kg; p.o.; single dose) significantly increases pentobarbital-induced sleep duration in male Sprague-Dawley rats, with sleep times of 134 minutes and 221 minutes respectively, indicating inhibition of hepatic pentobarbital metabolism^[3].
Norethynodrel (10-50 mg/kg; p.o.; daily; 4 days) does not induce hepatic microsomal enzymes in male Sprague-Dawley rats, but significantly reduces daily body weight gain^[3].
Norethynodrel (165 μg/kg/day; s.c.; continuous; 20 weeks) contributes a minor, statistically significant attenuation of isoproterenol-induced heart rate increases in female rats at specific time points, with ethinyl estradiol driving the primary attenuation effect^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

A/J Mice (female, virgin, initial weight 15-25 g, spontaneous mammary tumor model)^[2]
Dosage:

500 μg/20 g body weight (weeks 1-2); 250 μg/20 g body weight (weeks 3-5); 125 μg/20 g body weight (remainder up to 106 weeks)
Administration:

s.c.; twice weekly; up to 106 weeks
Result:

Reduced mean body weight throughout treatment compared to controls.
Increased mammary gland development mean score to 3.86.
Induced hyperplastic alveolar nodules (HAN) in over half of treated mice, compared to 1 nodule in controls.
Developed 8 type B mammary adenocarcinomas.
Developed 6 cervical carcinomas.
Caused suppressed ovulation, increased lipid-laden interstitial cells, ceroid pigment deposition, increased mean ovarian weight, and 5 ovarian tubular adenomas in ovaries.
Induced cystic glandular development with endometrial connective tissue hyalinization in uteri, more prominent than in controls.
Caused enlarged zona fasciculata cells with increased lipid content, and ceroid-containing cells at the corticomedullary boundary in all but 2 treated mice in adrenals.
Showed no pituitary cytological alterations or neoplasms.

Animal Model:

Sprague-Dawley (male, 110-180 g)^[3]
Dosage:

10 mg/kg; 50 mg/kg
Administration:

p.o.; daily; 4 days
Result:

Did not alter pentobarbital-induced sleep duration measured 24 hours after the last dose.
Caused no changes in hepatic microsomal protein per gram liver, cytochrome P-450 concentration, or cytochrome P-450 reductase activity.
Significantly decreased daily body weight gain, with weight gain suppressed relative to control rats across the 5-day monitoring period.

Animal Model:

Blue Spruce Farms rats (Sprague-Dawley derived) (female, 260-320 g)^[4]
Dosage:

165 μg/kg/day
Administration:

s.c.; continuous; 20 weeks
Result:

Observed a significant column effect on absolute heart rate at 50 and 60 minutes after isoproterenol administration.
Showed no significant interaction between norethynodrel and ethinyl estradiol throughout the treatment period.
Demonstrated a significant row effect on the change in heart rate from baseline only at 10 minutes post-isoproterenol.
Exhibited a significant interaction between norethynodrel and ethinyl estradiol on change in heart rate from baseline at 10 minutes post-isoproterenol.

Chemical Information

CAS. Nr. 68-23-5
Appearance Solid
Molecular Weight 298.42
Formel C₂₀H₂₆O₂
Color White to off-white
SMILES

C#C[C@]1(O)CC[C@@]2([H])[C@]3([H])CCC4=C(CCC(C4)=O)[C@@]3([H])CC[C@]12C
Synonyms

Enidrel; SC-4642; NSC 15432
Structure Classification
- Steroids
Initial Source
- Endogenous metabolite
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 1.6 mg/mL (5.36 mM; Need ultrasonic and warming; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.3510 mL

16.7549 mL

33.5098 mL

5 mM

0.6702 mL

3.3510 mL

6.7020 mL

10 mM

---

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (281 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Wienke Jr E C, Cavazos F, Hall D G, et al. Ultrastructural effects of norethynodrel and mestranol on human endometrial stroma cell[J]. American Journal of Obstetrics and Gynecology, 1969, 103(1): 102-111.

[2]. KAHN R H, et al. Effect of long-term treatment with Norethynodrel on A/J and C3H/HeJ mice[J]. Endocrinology, 1969, 84(3): 661-668.

[3]. Freudenthal R I, et al. The effect of norethynodrel, norethindrone and ethynodiol diacetate on hepatic microsomal drug metabolism[J]. Pharmacological Research Communications, 1974, 6(5): 457-468.

[4]. Fregly M J, et al. Response of heart rate to acute administration of isoproterenol in rats treated chronically with norethynodrel, ethinyl estradiol, and both combined[J]. Endocrinology, 1977, 100(1): 148-154.

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.3510 mL	16.7549 mL	33.5098 mL	83.7745 mL
DMSO	5 mM	0.6702 mL	3.3510 mL	6.7020 mL	16.7549 mL

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Norethynodrel

Alle Endogenous Metabolite Isoform-spezifische Produkte anzeigen